Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Middleton, Peter G., Mall, Marcus A., Dřevínek, Pavel, Lands, Larry C., McKone, Edward F., Polineni, Deepika, Ramsey, Bonnie W., Taylor-Cousar, Jennifer L., Tullis, Elizabeth, Vermeulen, François, Marigowda, Gautham, McKee, Charlotte M., Moskowitz, Samuel M., Nair, Nitin, Savage, Jessica, Simard, Christopher, Tian, Simon, Waltz, David, Xuan, Fengjuan, Rowe, Steven M., Jain, Raksha·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1908639

Cited by (2,225)

Items 501–600 of 2,225

A paradigm shift in cystic fibrosis nutritional care: Clinicians' views on the management of patients with overweight and obesity
J. Snowball, William George Flight, Laura Heath, Dimitrios A. Koutoukidis · 2023 · Journal of Cystic Fibrosis
CAGE sequencing reveals CFTR-dependent dysregulation of type I IFN signaling in activated cystic fibrosis macrophages
Jonathan L. Gillan, Mithil Chokshi, Gareth R. Hardisty, Sara Clohisey, Daniel Prasca-Chamorro, Nicola J. Robinson, Benjamin Lasota, Richard C. Clark, Lee Murphy, Moira K. B. Whyte et al. · 2023 · Science Advances
Cystic fibrosis modulator therapy can reverse cystic bronchiectasis
Peter Gordon Middleton, Nicholas J. Simmonds · 2023 · Respirology Case Reports
Delivering a New Future for People With Cystic Fibrosis
Elizabeth B. Burgener, David N. Cornfield · 2023 · PEDIATRICS
The modern landscape of fertility, pregnancy, and parenthood in people with cystic fibrosis
Raksha Jain, Traci M. Kazmerski, Jennifer L. Taylor‐Cousar · 2023 · Current Opinion in Pulmonary Medicine
Impact of CFTR modulator therapy on body composition as assessed by thoracic computed tomography: A follow-up study
Víctor Navas-Moreno, Fernando Sebastián‐Valles, Víctor Rodriguez Laval, Carolina Knott-Torcal, Mónica Marazuela, Nuria Sánchez de la Blanca, José Alfonso Arranz Martín, Rosa María Girón, Miguel Antonio Sampedro-Nuñez · 2024 · Nutrition
Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancy
Danni Li, Martin Donnelley, David Parsons, Mark D. Habgood, Elena K. Schneider‐Futschik · 2024 · British Journal of Pharmacology
Allosteric inhibition of CFTR gating by CFTRinh-172 binding in the pore
Xiaolong Gao, Han‐I Yeh, Zhengrong W. Yang, Chen Fan, Fan Jiang, Rebecca J. Howard, Erik R. Lindahl, John C. Kappes, Tzyh‐Chang Hwang · 2024 · Nature Communications
Artificial intelligence-driven volumetric CT outcome score in cystic fibrosis: longitudinal and multicenter validation with/without modulators treatment
Amel Imene Hadj Bouzid, S. Bui, Ilyès Benlala, Patrick Berger, Antoine Hutt, Renan Liberge, Paul Habert, Jean‐Yves Gaubert, Marie Baqué-Juston, Baptiste Morel et al. · 2024 · European Radiology
Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA
Elizabeth A. Cromwell, Josh S. Ostrenga, Don B. Sanders, Wayne J. Morgan, Carlo Castellani, Rhonda D. Szczesniak, Pierre‐Régis Burgel · 2024 · European Respiratory Journal
Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist
Saangyoung E. Lee, Zainab Farzal, M. Leigh Anne Daniels, Brian D. Thorp, Adam Mikial Zanation, Brent Anthony Senior, Charles S. Ebert, Adam J. Kimple · 2020 · American Journal of Rhinology and Allergy
CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation
Puay‐Wah Phuan, Peter M. Haggie, Joseph A. Tan, Amber A. Rivera, Walter E. Finkbeiner, Dennis W. Nielson, Merlin Marry Thomas, Ibrahim Ahmed Janahi, Alan S. Verkman · 2020 · Journal of Cystic Fibrosis
Lack of Kcnn4 improves mucociliary clearance in muco-obstructive lung disease
Génesis Vega, Anita Guequén, Amber R. Philp, Ambra Gianotti, Llilian Arzola Martínez, Manuel Villalón, Olga Zegarra‐Moran, Luis J. V. Galietta, Marcus Alexander Mall, Carlos Alberto Flores · 2020 · JCI Insight
P.F508del editing in cells from cystic fibrosis patients
Svetlana Smirnikhina, Ekaterina V. Kondrateva, Адильгереева Эльмира Пайзутдиновна, Arina A. Anuchina, Milyausha I. Zaynitdinova, Yana S. Slesarenko, Angelina S. Ershova, Kirill Ustinov, Matvei I. Yasinovsky, E. Amelina et al. · 2020 · PLoS ONE
Asthma in Cystic Fibrosis: Definitions and Implications of This Overlap Syndrome
Chad R. Marion, Manuel Izquierdo, Holly C. Hanes, Christopher Barrios · 2021 · Current Allergy and Asthma Reports
Modulation of Ion Transport to Restore Airway Hydration in Cystic Fibrosis
James A Reihill, Lisa Douglas, Lorraine Martin · 2021 · Genes
Changes in Care during the COVID-19 Pandemic for People with Cystic Fibrosis
Don B. Sanders, Runyu Wu, Tom O’Neil, Alexander Elbert, Kristofer Petren, Raksha Jain, Clement L. Ren · 2022 · Annals of the American Thoracic Society
Rechallenge of Elexacaftor/Tezacaftor/Ivacaftor After Skin Rash in Two Pediatric Patients
Emily R. Diseroad, Peter J. Mogayzel, Alice Pan · 2022 · The Journal of Pediatric Pharmacology and Therapeutics
Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis
Rosemary E Maher, Urszula Cytlak, Saad Aleem, Peter James Barry, Daniel Paul Brice, Eva Caamaño‐Gutiérrez, Kimberley Driver, Edward Emmott, Alex Rothwell, Emily Smith et al. · 2025 · Thorax
Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis
Jaime L. Rubin, Craig James McKinnon, Gabriel Pedra, Devon A. Morgan, Kimberly Zweig, Theodore G. Liou · 2025 · Pulmonary Therapy
Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two CFTR Class I variants: real-world data from the French compassionate programme
Pierre‐Régis Burgel, Emmanuelle Girodon, Neeraj Sharma, Caroline Raynal, Jennifer Da Silva, Souphatta Sasorith, Clémence Martin, Isabelle Sermet‐Gaudelus, Karen S. Raraigh · 2025 · EClinicalMedicine
International Society for Heart and Lung Transplantation Consensus Statement on the Referral and Selection of Pediatric Lung Transplant Candidates
Don Hayes, Nicholas Avdimiretz, Rossa E. Brugha, Mary P. Mullen, Miranda A. Paraskeva, Levent Mıdyat, Melinda P. Solomon, Stuart Charles Sweet, Ernestina Melicoff, Lara A. Danziger‐Isakov et al. · 2025 · The Journal of Heart and Lung Transplantation
Rationale and design of the HIT-CF organoid study: stratifying cystic fibrosis patients based on intestinal organoid response to different CFTR-modulators
Peter van Mourik, Sabine Heida-Michel, Annelotte M. Vonk, Jeffrey Matthijn Beekman, Cornelis Korstiaan van der Ent, Hilde DeKeyser, Elise J. Lammertyn, Silke V. Koningsbruggen-Rietschel, Lutz Naehrlich, Judith Pool et al. · 2020 · Translational Medicine Communications
A small molecule CFTR potentiator restores ATP‐dependent channel gating to the cystic fibrosis mutant G551D‐CFTR
Jia Liu, Allison P. Berg, Yiting Wang, Walailak Jantarajit, Katy J. Sutcliffe, Edward Boucher Stevens, Lishuang Cao, Marko J. Pregel, David N. Sheppard · 2021 · British Journal of Pharmacology
Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis
Iram Haq, Maryam M. Almulhem, Simone Soars, David Poulton, Malcolm Brodlie · 2022 · Pharmacogenomics and Personalized Medicine
Acneiform Eruption Following Elexacaftor-Tezacaftor-Ivacaftor Treatment in Patients With Cystic Fibrosis
L. Okroglic, Pierre Sohier, Clémence Martin, C. Lheure, Nathalie Franck, Isabelle Honoré, R. Kanaan, Pierre‐Régis Burgel, A. Carlotti, Nicolas Dupin et al. · 2022 · JAMA Dermatology
Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease
Alessandro Giallongo, Giuseppe Fabio Parisi, Maria Rosaria Papale, Sara Manti, Enza Mulè, Donatella Aloisio, Vito Terlizzi, Novella Rotolo, Salvatore Leonardi · 2023 · Genes
Cystic Fibrosis–Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes
Melissa S. Putman, Andrew W. Norris, Rebecca L. Hull, Michael Roehrhoff Rickels, Lori Sussel, Scott M. Blackman, Christine L. Chan, Katie Larson Ode, Tanicia C. Daley, Arlene A. Stecenko et al. · 2023 · Diabetes
Ocular development after highly effective modulator treatment early in life
Yimin Zhu, Danni Li, Felisa Reyes‐Ortega, Holly Rose Chinnery, Elena K. Schneider‐Futschik · 2023 · Frontiers in Pharmacology
A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation
Carolina Knott-Torcal, Fernando Sebastián‐Valles, Rosa María Girón, Jose Carlos Martin-Adan, Jessica Jiménez‐Díaz, Mónica Marazuela, Nuria Sánchez de la Blanca, Raúl Fernández-Contreras, Alfonso Arranz Martín · 2023 · Clinical Nutrition
Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis
Peter Nickolaus, Birgit Jung, Juan R. Sabater, Samuel Constant, Abhya Gupta · 2020 · ERJ Open Research
Management of pregnancy in cystic fibrosis
Kristina Montemayor, Elizabeth D. Tullis, Raksha Jain, Jennifer L. Taylor‐Cousar · 2022 · Breathe
Targeting trafficking as a therapeutic avenue for misfolded GPCRs leading to endocrine diseases
Alfredo Ulloa‐Aguirre, Teresa Zariñán, Rubén Gutiérrez‐Sagal, Ya‐Xiong Tao · 2022 · Frontiers in Endocrinology
The CFTR Amplifier Nesolicaftor Rescues TGF-β1 Inhibition of Modulator-Corrected F508del CFTR Function
Charles D. Bengtson, Neerupma Silswal, Nathalie Baumlin, Makoto Yoshida, John Dennis, Sireesha Yerrathota, Michael D. Kim, Matthias A. Salathe · 2022 · International Journal of Molecular Sciences
Specific circulating neutrophils subsets are present in clinically stable adults with cystic fibrosis and are further modulated by pulmonary exacerbations
Clémence Martin, Théo Dhôte, Maha Zohra Ladjemi, Muriel Andrieu, Souganya Many, Vaarany Karunanithy, Frédéric Pène, Jennifer Da Silva, Pierre‐Régis Burgel, Véronique Witko‐Sarsat · 2022 · Frontiers in Immunology
Sustained recovery of exocrine pancreatic function in a teenager with cystic fibrosis treated with ivacaftor
Haley Smith, Jonathan H. Rayment · 2020 · Pediatric Pulmonology
Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators
Burkhard Tümmler, Sophia Theres Pallenberg, Anna‐Maria Dittrich, Simon Y. Graeber, Lutz Naehrlich, Olaf Sommerburg, Marcus Alexander Mall · 2025 · Molecular and Cellular Pediatrics
Measuring the effect of elexacaftor/tezacaftor/ivacaftor combination therapy on the respiratory pump in people with CF using dynamic chest radiography
Thomas Simon FitzMaurice, Caroline A. McCann, Dilip S. Nazareth, Matthew Shaw, Paul Stephen McNamara, Martin John Walshaw · 2022 · Journal of Cystic Fibrosis
CFTR modulator therapy alters plasma sphingolipid profiles in people with cystic fibrosis
Dirk Westhölter, Fabian Schumacher, N Wülfinghoff, Sivagurunathan Sutharsan, Svenja Straßburg, Burkhard Kleuser, Peter Alexander Horn, Sebastian Reuter, Erich Gulbins, Christian Taube et al. · 2022 · Journal of Cystic Fibrosis
Cystic fibrosis related diabetes (CFRD) in the era of modulators: A scoping review
Bernadette J. Prentice, Michael Nicholson, Grace Y. Lam · 2022 · Paediatric Respiratory Reviews
Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy
Frauke Stanke, Sophia Theres Pallenberg, Stephanie Tamm, Silke Hedtfeld, Ella M. Eichhorn, Rebecca Minso, Gesine Hansen, Tobias Welte, Annette Sauer‐Heilborn, Felix C. Ringshausen et al. · 2023 · Frontiers in Pharmacology
Sweat induction using Pilocarpine microneedle patches for sweat testing in healthy adults
Jonathan Yuxuan Chen, Song Li, George L. Silva, Joshua D. Chandler, Mark R. Prausnitz, Lokesh Guglani · 2023 · Journal of Cystic Fibrosis
Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications
Eunjin Hong, Alan Shi, Paul M. Beringer · 2023 · Expert Opinion on Drug Metabolism & Toxicology
Experience With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Disease
Laura Carrasco Hernández, Rosa María Girón, María Nieves Balaguer Cartagena, Adrián Peláez, Amparó Solé, Antonio Álvarez Fernández, Almudena Felipe Montiel, Casilda Olveira, Gabriel Olveira, Ainhoa Gómez Bonilla et al. · 2023 · Archivos de Bronconeumología
Evolving Nutritional Needs in Cystic Fibrosis
T. Frantzen, Sara Barsky, Geralyn LaVecchia, Michelle Marowitz, Janice Wang · 2023 · Life
The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?
Kathryn E. Oliver, Marianne Sylvia Carlon, Nicoletta Pedemonte, Miquéias Lopes‐Pacheco · 2023 · Expert Opinion on Pharmacotherapy
In silico analysis and theratyping of an ultra-rare CFTR genotype (W57G/A234D) in primary human rectal and nasal epithelial cells
Karina Kleinfelder, Virginia Lotti, Adriana Eramo, Felice Amato, Stefania Lo Cicero, Germana Castelli, Francesca Spadaro, Alessia Farinazzo, Daniele Dell’Orco, Sara Preato et al. · 2023 · iScience
ECFS standards of care on CFTR-related disorders: Towards a comprehensive program for affected individuals
Elke De Wachter, K. De Boeck, Isabelle Sermet‐Gaudelus, Nicholas J. Simmonds, À. Munck, Lutz Naehrlich, Juerg Barben, Cynthia M. Boyd, SJ Veen, S.B. Carr et al. · 2024 · Journal of Cystic Fibrosis
The Folding Pathway of ABC Transporter CFTR: Effective and Robust
Peter van der Sluijs, Hanneke Hoelen, André Schmidt, Ineke Braakman · 2024 · Journal of Molecular Biology
Changes in exercise capacity in people with Cystic Fibrosis after one year of Elexacaftor/Tezacaftor/Ivacaftor treatment – A Danish prospective cohort
Lue Katrine Drasbæk Philipsen, Hanne Vebert Olesen, Janne Hastrup Jensen, Mette Frahm Olsen, Daniel Faurholt‐Jepsen, Frederik Fouirnaies Buchvald, Kim G. Nielsen, Marianne Skov, Tacjana Pressler · 2024 · Journal of Cystic Fibrosis
The clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) for people with CF without a F508del variant: A systematic review and meta-analysis
Dániel Lupas, Frank Y. Chou, Mohammad Abdullah Al Hakani, Ishita Kuthiala, Arjuna Srikrishnaraj, Xuan Li, Naomi Potter, Bradley S. Quon · 2024 · Journal of Cystic Fibrosis
Gene expression responses of CF airway epithelial cells exposed to elexacaftor/tezacaftor/ivacaftor suggest benefits beyond improved CFTR channel function
Thomas H. Hampton, Roxanna Barnaby, Carolyn Roche, Amanda B. Nymon, Kiyoshi F. Fukutani, Todd A. MacKenzie, Lily A. Charpentier, Bruce A. Stanton · 2024 · American Journal of Physiology-Lung Cellular and Molecular Physiology
Re-imagining cystic fibrosis care: next generation thinking
Catherine Rang, D. Keating, John W. Wilson, Tom C. Kotsimbos · 2020 · European Respiratory Journal
Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders’ consensus view
K. De Boeck, T. Lee, Margarida Duarte Amaral, Pavel Dřevı́nek, J.S. Elborn, Isabelle Fajac, Eitan Kerem, Jane Carolyn Davies · 2020 · Journal of Cystic Fibrosis
Functional Profiling of CFTR-Directed Therapeutics Using Pediatric Patient-Derived Nasal Epithelial Cell Models
Jeffrey KiHyun Park, Anura Shrivastava, Chengkang Zhang, Brian A. Pollok, Walter E. Finkbeiner, Elizabeth R. Gibb, Ngoc P. Ly, Beate Illek · 2020 · Frontiers in Pediatrics
Elexacaftor–tezacaftor–ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation
Andrea Gramegna, Martina Contarini, Francesco Bindo, Stefano Aliberti, Francesco Blasi · 2021 · Current Opinion in Pharmacology
Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?
Claire L. Edmondson, Christopher William Course, Iolo J.M. Doull · 2021 · Archives of Disease in Childhood
Prevalence, Characteristics and Preoperative Predictors of Chronic Pain After Double-Lung Transplantation: A Prospective Cohort Study
Quentin Laurent, Mireille Michel-Cherqui, Barbara Székély, Matthieu Glorion, Édouard Sage, Julie Trichereau, Marc Fischler, Julien Fessler, Morgan Le Guen · 2021 · Journal of Cardiothoracic and Vascular Anesthesia
How the sweat gland reveals levels of CFTR activity
Jeffrey J. Wine · 2022 · Journal of Cystic Fibrosis
Mucus and mucus flake composition and abundance reflect inflammatory and infection status in cystic fibrosis
Matthew R. Markovetz, Ian C. Garbarine, Cameron B. Morrison, William J. Kissner, Ian Seim, M. Gregory Forest, Micah Papanikolas, Ronit Freeman, Agathe Ceppe, Andrew J. Ghio et al. · 2022 · Journal of Cystic Fibrosis
An optimized protocol for assessment of sputum macrorheology in health and muco-obstructive lung disease
Mirjam Völler, Annalisa Addante, Hanna Rulff, Benjamin von Lospichl, Simon Y. Gräber, Julia Duerr, Daniel Christian Lauster, Rainer Haag, Michael Gradzielski, Marcus Alexander Mall · 2022 · Frontiers in Physiology
Advent of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis treatment: What consequences on Aspergillus-related diseases? Preliminary insights
Adélaïde Chesnay, Éric Bailly, Laure Cosson, Thomas Flament, Guillaume Désoubeaux · 2022 · Journal of Cystic Fibrosis
Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals
Maryam M. Almulhem, Nuala Harnett, Stephanie Graham, Iram J. Haq, Shelina Visram, Chris Ward, Malcolm Brodlie · 2022 · BMJ Open Respiratory Research
Drug Repurposing for Cystic Fibrosis: Identification of Drugs That Induce CFTR-Independent Fluid Secretion in Nasal Organoids
Lisa W. Rodenburg, Livia Delpiano, Violeta Railean, Raquel Centeio, Madalena C. Pinto, Shannon M.A. Smits, Isabelle S. van der Windt, Casper F. J. van Hugten, Sam F.B. van Beuningen, Remco N. P. Rodenburg et al. · 2022 · International Journal of Molecular Sciences
Rectal organoid-guided CFTR modulator therapy restores lung function in a cystic fibrosis patient with the rare 1677delTA/R334W genotype
Georgia Mitropoulou, Nathalie Brandenberg, Sylke Hoehnel, Camilla Ceroni, Zisis Balmpouzis, Sylvain Blanchon, Gian O. Dorta, Alain Sauty, Angela Koutsokera · 2022 · European Respiratory Journal
Impact of chronic medication de-escalation in patients with cystic fibrosis taking elexacaftor, tezacaftor, ivacaftor: A retrospective review
Emma L. Guenther, Karen McCoy, Mariah Eisner, Shasha Bai, Christopher J. Nemastil, Kimberly J. Novak, Terri Johnson, Emily M. Stephan · 2023 · Journal of Cystic Fibrosis
Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes
Fabian O. Lurquin, Sophie T. Gohy, Michel Paul Hermans, Vanessa Preumont · 2023 · Journal of Clinical & Translational Endocrinology
Progress in Model Systems of Cystic Fibrosis Mucosal Inflammation to Understand Aberrant Neutrophil Activity
Daniel R. Laucirica, Luke W. Garratt, Anthony Kicic · 2020 · Frontiers in Immunology
Mycobacterium abscessus in cystic fibrosis
Rossa E. Brugha, Helen Spencer · 2021 · Science
Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist
Michael M. Tunney, Peter A. B. Wark · 2023 · European Respiratory Journal
ATP-Binding Cassette and Solute Carrier Transporters: Understanding Their Mechanisms and Drug Modulation Through Structural and Modeling Approaches
Ahmad Elbahnsi, Bálint Dudás, Isabelle Callebaut, Alexandre Hinzpeter, Maria A. Miteva · 2024 · Pharmaceuticals
Sweat chloride and lung function responses to elexacaftor–tezacaftor–ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies
Pierre‐Régis Burgel, Jennifer Da Silva, Emmanuelle Girodon, I. Durieu, Martine Reynaud‐Gaubert, M. Murris‐Espin, R. Chiron, Dominique Grenet, Sophie Ramel, Laurent Mély et al. · 2025 · The Lancet Respiratory Medicine
Optimizations of In Vitro Mucus and Cell Culture Models to Better Predict In Vivo Gene Transfer in Pathological Lung Respiratory Airways: Cystic Fibrosis as an Example
Rosy Ghanem, Véronique Laurent, Philippe Roquefort, Tanguy Haute, Sophie Ramel, Tony Le Gall, Thierry Aubry, Tristan Montier · 2020 · Pharmaceutics
Stability Prediction for Mutations in the Cytosolic Domains of Cystic Fibrosis Transmembrane Conductance Regulator
Malkeet Singh Bahia, Netaly Khazanov, Qingxian Zhou, Zhengrong W. Yang, Chi Chiu Wang, Jeong Shin Hong, András Rab, Eric J. Sorscher, Christie G. Brouillette, John Francis Hunt et al. · 2021 · Journal of Chemical Information and Modeling
Limitations of standard cost-effectiveness methods for health technology assessment of treatments for rare, chronic diseases: a case study of treatment for cystic fibrosis
Jaime L. Rubin, Andrea Lopez, Jason Booth, Penilla Gunther, Anupam Bapu Jena · 2022 · Journal of Medical Economics
How many billions is enough? Prioritizing profits over patients with cystic fibrosis
Meghan E. McGarry, Elizabeth R. Gibb, Theresa Annette Laguna, Brian P. O'Sullivan, Gregory S. Sawicki, Jeffery T. Zobell · 2023 · Pediatric Pulmonology
Pregnancy in Cystic Fibrosis—Past, Present, and Future
Michal Gur, Mordechai Pollak, Ronen Bar‐Yoseph, Lea Bentur · 2023 · Journal of Clinical Medicine
The Clinical Association between Aspergillus fumigatus and Respiratory Outcomes in Adolescents and Adults with Cystic Fibrosis
Anna L. O’Dea, Rui Feng, Laurel J. Glaser, Christina Kubrak, Ronald C. Rubenstein, Daniel J. Dorgan, Denis Hadjiliadis, Steven M. Kawut, Gina Hong · 2023 · Annals of the American Thoracic Society
Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy
Giuseppe G. Cimino, Sara Sorrenti, Manuel Murciano, Paola Galoppi, Fiorentina Ascenzioni, Bruno Botta, Roberto Brunelli, Luca Cavinato, Andrea Cerrato, Gabriele Cianfoni et al. · 2023 · Archives of Gynecology and Obstetrics
Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis
Landon Marshall, Rachel Espinosa, Catherine I. Starner, Patrick P. Gleason · 2023 · Journal of Managed Care & Specialty Pharmacy
Multimodal analysis of granulocytes, monocytes, and platelets in patients with cystic fibrosis before and after Elexacaftor–Tezacaftor–Ivacaftor treatment
Hanna Schmidt, Larissa Melina Höpfer, Lisa Wohlgemuth, Christiane Leonie Knapp, Adam Omar Khalaf Mohamed, Laura Stukan, Frederik Münnich, Dominik Hüsken, Alexander Sebastian Koller, Alexander Elias Paul Stratmann et al. · 2023 · Frontiers in Immunology
The effect of elexacaftor/tezacaftor/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis
Sarah Allgood, Reena Levy, Despina Bubaris, Kristin A. Riekert, Kevin J. Psoter, Noah Lechtzin · 2023 · Heliyon
The cystic fibrosis treatment Trikafta affects the growth, viability, and cell wall of Aspergillus fumigatus biofilms
Jane Tully Jones, Kaesi A. Morelli, Elisa M. Vesely, Charles T.S. Puerner, Chetan K. Pavuluri, Brandon S. Ross, Norman van Rhijn, Michael Bromley, Robert A. Cramer · 2023 · mBio
Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms
Luyang Cao, Yong Wu, Yanchun Gong, Qingfa Zhou · 2024 · European Journal of Medicinal Chemistry
Elexacaftor/tezacaftor/ivacaftor improves chronic rhinosinusitis detected by magnetic resonance imaging in children with cystic fibrosis on long-term therapy with lumacaftor/ivacaftor
Lena Wucherpfennig, Johanna K.Z. Becker, Felix Wuennemann, Monika Eichinger, Angelika Seitz, Ingo Baumann, Mirjam Stahl, Simon Y. Graeber, Shengkai Zhao, Jaehi Chung et al. · 2024 · Journal of Cystic Fibrosis
Diagnosing Cystic Fibrosis in the 21st Century—A Complex and Challenging Task
Dana-Teodora Anton-Păduraru, Alice Nicoleta Azoicai, Felicia Trofin, Dana Elena Mîndru, Alina Mariela Murgu, Ana Simona Bocec, Codruța-Olimpiada Halițchi-Iliescu, Carmen Iulia Ciongradi, Ioan Sârbu, Maria Liliana Iliescu · 2024 · Diagnostics
ACE-tRNAs are a platform technology for suppressing nonsense mutations that cause cystic fibrosis
Wooree Ko, Joseph J. Porter, Sacha Spelier, Emily G. Sorensen, Priyanka Bhatt, J. Gabell, Isabelle S. van der Windt, Tyler A. Couch, Kevin J. Coote, Martin Mense et al. · 2025 · Nucleic Acids Research
Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease
Matthew D. Strub, Paul B. McCray · 2020 · Genes
Lumacaftor/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis
Susannah J. King, D. Keating, E. Williams, Eldho Mathew Paul, Brigitte M. Borg, F. Finlayson, Brenda Button, John W. Wilson, Tom C. Kotsimbos · 2020 · ERJ Open Research
An open-source high-content analysis workflow for CFTR function measurements using the forskolin-induced swelling assay
Marne C. Hagemeijer, Annelotte M. Vonk, Nikhil T Awatade, Iris A. L. Silva, Christian Tischer, Volker Hilsenstein, Jeffrey Matthijn Beekman, Margarida Duarte Amaral, Hugo M. Botelho · 2020 · Bioinformatics
Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis
Dirk Westhölter, Hendrik Beckert, Svenja Straßburg, Matthias Welsner, Sivagurunathan Sutharsan, Christian Taube, Sebastian Reuter · 2021 · Journal of Cystic Fibrosis
Novel Immunomodulatory Therapies for Respiratory Pathologies
Luciana P. Tavares, Izabela Galvão, Maximiliano Ruben Ferrero · 2021 · Elsevier eBooks
Apparent Yield Stress of Sputum as a Relevant Biomarker in Cystic Fibrosis
Rosy Ghanem, Philippe Roquefort, Sophie Ramel, Véronique Laurent, Tanguy Haute, Tony Le Gall, Thierry Aubry, Tristan Montier · 2021 · Cells
Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis
Mitchell L. Ramsey, Michael R. Wellner, Kyle M. Porter, Stephen E. Kirkby, Susan S. Li, Luis F. Lara, Sean G. Kelly, A. James Hanje, Lindsay A. Sobotka · 2022 · World Journal of Hepatology
Incidence of transaminitis in adults with cystic fibrosis taking elexacaftor/tezacaftor/ivacaftor
Marci Wood, Faith Babowicz, Amanda G. Kennedy, M. Antell, Elizabeth Gilhooly, Bradley J. Tompkins, Sheela S. Reddy · 2023 · Journal of the American Pharmacists Association
Inflammation as a Regulator of the Airway Surface Liquid pH in Cystic Fibrosis
Tayyab Rehman, Michael J. Welsh · 2023 · Cells
Mechanism of dual pharmacological correction and potentiation of human CFTR
Chi Wang, Zhengrong W. Yang, Blaine J. Loughlin, Haijin Xu, Guido Veit, Sergey M. Vorobiev, Oliver B. Clarke, Fan Jiang, Yaohui Li, Shikha Singh et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
Airway clearance and exercise for people with cystic fibrosis: balancing longevity with life
Rowbotham, Nicola J., Daniels, Tracey E. · 2022 · Pediatric Pulmonology
Perinatal dysfunction of innate immunity in cystic fibrosis
Florian Jaudas, Florian Bartenschlager, Bachuki Shashikadze, Gianluca Santamaria, Daniel Reichart, Alexander Schnell, Jan B. Stöckl, Roxane L. Degroote, Josep M. Cambra, Simon Y. Graeber et al. · 2025 · Science Translational Medicine
Respiratory infections after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis: analysis of the European Cystic Fibrosis Society Patient Registry
Mordechai Pollak, Simone Gambazza, Annalisa Orenti, Virginia De Rose, Dario Prais, Eitan Kerem, Meir Mei‐Zahav · 2025 · ERJ Open Research